DEFM14A: Akero Therapeutics to Merge with Novo Nordisk Subsidiary

Akero Therapeutics stockholders are invited to a special meeting on December 2, 2025, to vote on the proposed acquisition by Novo Nordisk A/S for $54.00 cash per share plus a $6.00 contingent value right.

Summary

• Akero Therapeutics, Inc. (Akero) is being acquired by Novo Nordisk A/S (Novo) through its wholly owned subsidiary, NN Invest Sub, Inc (Merger Sub).
• Each outstanding share of Akero common stock will be converted into the right to receive $54.00 in cash (Closing Consideration) and one Contingent Value Right (CVR).
• Each CVR represents a non-transferable contractual right to receive an additional $6.00 in cash (Approval Milestone Payment) if FDA approval for efruxifermin for subcutaneous injection for the treatment of patients with compensated cirrhosis (F4c fibrosis) due to metabolic dysfunction-associated steatohepatitis (MASH) is received by June 30, 2031.
• The Akero Board of Directors unanimously recommends that stockholders vote FOR the Merger Proposal, the Compensation Proposal, and the Adjournment Proposal.
• A special meeting of stockholders will be held virtually on December 2, 2025, at 11:00 a.m. Eastern Time, with November 7, 2025, as the record date.
• The merger is expected to be completed by around year-end 2025, subject to stockholder and regulatory approvals.
• The $54.00 Closing Consideration represents a premium of approximately 42% over Akero's closing price of $38.14 per share on May 19, 2025 (the last trading day prior to media speculation of a potential transaction).
• The $54.00 Closing Consideration also represents a premium of approximately 19% over the volume-weighted average share price over the 30-trading day period preceding and including October 8, 2025.

Sentiment

Score: 8

Explanation: The acquisition offers a substantial premium and a CVR upside, backed by unanimous board approval and fairness opinions. While CVR is contingent and equity interest is lost, it addresses standalone risks for a clinical-stage company with a single lead product.

Positives

• Stockholders receive immediate liquidity and certainty of value with $54.00 cash per share.
• The cash consideration offers a significant premium: 42% over the May 19, 2025 closing price ($38.14) and 19% over the 30-trading day volume-weighted average price preceding October 8, 2025.
• An opportunity for additional value of $6.00 per share is provided via a CVR if efruxifermin achieves FDA approval for the specified MASH indication by June 30, 2031.
• Novo Nordisk commits to using 'Commercially Reasonable Efforts' to conduct the SYNCHRONY Histology and SYNCHRONY Outcomes clinical trials and seek FDA approval for efruxifermin.
• Novo Nordisk's extensive experience and resources in drug development and commercialization are expected to enhance the likelihood of achieving the CVR milestone.
• The merger is not conditioned on any financing arrangements, with Novo Nordisk confirming sufficient available funds.
• The Board of Directors unanimously determined the merger is advisable and fair to, and in the best interest of, Akero and its stockholders.
• The terms of the Merger Agreement were the result of robust arms-length negotiations, leading to an improved offer from Novo Nordisk and an extended CVR deadline.
• A reverse termination fee of $185,000,000 is payable by Novo Nordisk to Akero under certain regulatory termination circumstances.

Negatives

• CVRs are non-transferable, not registered with the SEC, and will not be listed for trading, limiting liquidity and market valuation.
• There is no guarantee that the Approval Milestone for the CVR will be achieved by the Termination Date (June 30, 2031) or at all, meaning stockholders may not receive the additional $6.00 per CVR.
• Akero's public stockholders will have no ongoing equity interest in the surviving corporation, meaning they will cease to participate in Akero's potential future earnings or growth.
• The Merger Agreement contains covenants prohibiting Akero from soliciting other potential Acquisition Proposals, potentially limiting better offers, though it includes customary fiduciary out provisions.
• Akero may be required to pay a termination fee of $165,000,000 to Novo Nordisk under certain circumstances, such as accepting a superior offer or the Board changing its recommendation.
• The reverse termination fee from Novo Nordisk is not available in all termination scenarios.
• The public announcement of the merger could distract Akero's employees, limit its ability to attract and retain key personnel, and disrupt relationships with business partners.
• There is a risk of litigation in connection with the merger, which, even if lacking merit, could result in distraction and expense.
• Interim operating covenants impose restrictions on Akero's business conduct prior to closing, potentially delaying or preventing the pursuit of certain business strategies or opportunities.
• The merger requires certain regulatory clearances, which could lead to unforeseen delays or conditions, and Novo Nordisk is not required to agree to certain structural undertakings.
• The receipt of cash and CVRs by stockholders in exchange for common stock will generally be a taxable transaction for U.S. federal income tax purposes.

Risks

• Uncertainties regarding the achievement of the CVR Approval Milestone by June 30, 2031, or at all, meaning no CVR payment may be received.
• CVRs are non-transferable and not publicly traded, limiting liquidity and market valuation.
• Loss of future equity participation in Akero's potential growth and earnings for current stockholders.
• Potential for significant decline in Akero's stock price if the merger is not completed.
• Risks associated with obtaining FDA approval for efruxifermin for MASH (compensated cirrhosis F4c), including timing delays, regulatory hurdles, and costs.
• Reliance on third parties to conduct, supervise, and monitor clinical trials, manufacture, and supply efruxifermin and its delivery device, and to protect proprietary technology.
• Challenges in transitioning from a clinical-stage biotechnology company to a larger organization with commercialization capabilities if the merger does not proceed.
• Efruxifermin is Akero's only product candidate, posing a concentration risk.
• Akero has incurred net losses since its inception and expects to continue doing so, with significant capital investment required for standalone operations, potentially leading to highly dilutive future debt or equity financing.
• Competitive landscape with large global pharmaceutical companies pursuing MASH treatments, some having recently acquired competitors with similar product mechanisms.
• Restrictions on Akero's business operations during the pre-closing period, potentially hindering new business strategies or opportunities.
• Risk of litigation in connection with the execution of the Merger Agreement and the consummation of the Merger.
• Regulatory approval process for the merger itself, including potential delays, conditions, or challenges from governmental bodies, with Novo Nordisk not required to agree to certain structural undertakings.
• Uncertainty in U.S. federal income tax treatment of CVRs.

Future Outlook

The merger is expected to be completed by around year-end 2025, contingent upon stockholder and regulatory approvals. Novo Nordisk commits to using commercially reasonable efforts to advance efruxifermin through the SYNCHRONY Histology and SYNCHRONY Outcomes clinical trials and, upon achieving primary endpoints, to seek FDA approval for the product for compensated cirrhosis (F4c fibrosis) due to MASH by June 30, 2031. However, there is no guarantee that the Approval Milestone will be achieved or that CVR holders will receive any payment. If the merger is not completed, Akero will remain an independent public company, continuing its standalone strategy, which involves significant execution risks, substantial capital investment, and potential dilutive financing to achieve profitability.

Management Comments

• Andrew Cheng, President and CEO: "On behalf of the Board of Directors, I thank you for your support and appreciate your consideration of this matter."
• The Board of Directors unanimously determined that the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, are advisable and fair to, and in the best interest of, Akero and its stockholders.
• The Board of Directors unanimously recommends that stockholders vote FOR the Merger Proposal, FOR the Compensation Proposal, and FOR the Adjournment Proposal.

Industry Context

Akero Therapeutics, a clinical-stage company focused on metabolic diseases like MASH, is being acquired by Novo Nordisk, a global healthcare leader. This acquisition aligns with a broader industry trend where large pharmaceutical companies are acquiring promising clinical-stage biotechs to bolster their pipelines, particularly in areas of high unmet medical need such as MASH. The filing notes that other major pharmaceutical companies are actively developing MASH treatments and have recently acquired competitors with similar product mechanisms, indicating a competitive and consolidating market. Novo Nordisk's substantial resources and expertise are expected to accelerate the development and potential commercialization of efruxifermin, a task Akero, as a standalone company with limited capital and a single lead product, might struggle to achieve at a comparable pace.

Comparison to Industry Standards

• The $54.00 upfront cash consideration represents a premium of approximately 42% over Akero's closing price on May 19, 2025 (pre-speculation) and 19% over the 30-trading day volume-weighted average share price preceding October 8, 2025, which are generally considered attractive premiums in biopharmaceutical acquisitions.
• The inclusion of a Contingent Value Right (CVR) for an additional $6.00 upon FDA approval of efruxifermin for compensated cirrhosis (F4c fibrosis) due to MASH by June 30, 2031, is a common deal structure in biotech M&A, allowing for shared future clinical and regulatory success with selling shareholders for late-stage assets.
• The Board considered the 'estimated risk-adjusted value' of the offer and the 'premium this value represented over the current trading price,' indicating a valuation process consistent with industry standards for M&A transactions.
• The termination fee of $165,000,000 and reverse termination fee of $185,000,000 are within typical ranges for transactions of this size, reflecting standard risk allocation in merger agreements.
• The filing highlights that 'certain of these large global pharmaceutical companies had recently acquired other clinical stage biotechnology companies with product candidates that target MASH or metabolic diseases associated with MASH, including two acquired companies with products with a similar mechanism of action as efruxifermin,' suggesting this acquisition is consistent with recent M&A activity in the MASH therapeutic area.

Management Changes

Corporate Governance

Legal Proceedings

• The Board of Directors discussed a books and records demand under Section 220 of the DGCL, served on September 20, 2024, alleging overpayment of non-employee directors. The Board concluded these claims had no value and should not affect the decision to sell the company.
• There is a risk of litigation in connection with the execution of the Merger Agreement and the consummation of the Merger, which, even if lacking in merit, could nonetheless result in distraction and expense.

Related Party Transactions

• Akero's executive officers and directors have interests in the merger that differ from general stockholders, including accelerated vesting of Company Options and Company RSUs.
• Executive officers are eligible to receive severance payments and benefits under employment agreements in connection with a qualifying termination of employment within twelve months following a change in control (the Merger).
• One executive officer may receive reimbursement for excise taxes incurred under Section 4999 of the Code in connection with the transactions, up to an aggregate amount of $600,000.
• The 2025 annual cash bonus may be determined and paid prior to closing at the 100% level of achievement for executive officers.
• Continuing indemnification, advancement of expenses, and exculpation from liabilities for directors and officers will be maintained for six years from the Effective Date.

Stakeholder Impact

• **Shareholders**: Will receive $54.00 cash per share and one CVR (potential $6.00 additional cash) for each share, providing immediate liquidity and potential upside. They will lose ongoing equity interest in Akero. Dissenting shareholders have appraisal rights.
• **Employees**: Executive officers may receive severance payments and benefits upon qualifying termination post-merger. All employees continuing with the Surviving Corporation will receive comparable base salary, target annual/short-term cash incentives, and substantially similar broad-based benefits for one year.
• **Management**: Executive officers have potential severance and accelerated equity vesting. Akero's current directors and officers will be replaced by those of Merger Sub upon completion of the merger.
• **Customers/Patients**: The merger aims to accelerate the development and potential commercialization of efruxifermin for MASH, potentially benefiting patients with this unmet medical need through Novo Nordisk's resources.
• **Suppliers/Partners**: Relationships with business partners could be disrupted by the announcement or pendency of the merger, though Akero is required to use reasonable best efforts to obtain necessary consents.

Next Steps

• Akero stockholders are to vote on the Merger Proposal, Compensation Proposal, and Adjournment Proposal at a Special Meeting on December 2, 2025.
• The merger is anticipated to be completed by around year-end 2025, subject to stockholder and regulatory approvals.
• Novo Nordisk is committed to using commercially reasonable efforts to conduct the SYNCHRONY Histology and SYNCHRONY Outcomes clinical trials and seek FDA approval for efruxifermin for compensated cirrhosis (F4c fibrosis) due to MASH.
• If the merger is not completed, Akero will remain an independent public company, and its Board will continue to evaluate strategic alternatives.

Key Dates

Recommendation

The acquisition offers a substantial premium (42% over pre-speculation price, 19% over 30-day VWAP) and immediate cash liquidity for stockholders. The inclusion of a CVR provides additional upside potential ($6.00 per share) tied to FDA approval of efruxifermin, a key asset, which will benefit from Novo Nordisk's significant development and commercialization resources. This transaction de-risks Akero's standalone execution and financing challenges as a clinical-stage company with a single lead product. The unanimous board recommendation and fairness opinions from two financial advisors further support the attractiveness of the offer. Given the current stock price of $53.91 (as of Nov 6, 2025) is below the $54 cash component, let alone the potential $6 CVR, it presents a low-risk entry for investors to capture the premium and CVR upside.

Keywords

Akero Therapeutics, Novo Nordisk, Merger Agreement, Acquisition, Contingent Value Rights, Efruxifermin, MASH, FDA Approval, Clinical Trials, Biotechnology, Pharmaceutical, Corporate Governance, Stockholder Vote